Information sur le laboratoire
Waqqas Afif (M.D./M.Sc.)
ChercheurUnité de recherche clinique
Département de médecine (McGill)
Profil de recherche
Mots-clés
Maladie inflammatoire chronique de l'intestin • maladie de Crohn • colite ulcéreuse • médicaments biologiques • contrôle des médicaments thérapeutiquesIntérêts de recherche
Ma recherche porte sur la sécurité et l'efficacité des médicaments biologiques dans le traitement de la maladie inflammatoire chronique de l'intestin. Je m'intéresse au contrôle des médicaments thérapeutiques afin d'optimiser le traitement des patients atteints de la maladie inflammatoire chronique de l'intestin prenant des médicaments biologiques.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Lichtenstein, G. R., Allegretti, J. R., Rubin, D. T., Magro, F., Bressler, B., Panés, J., Afif, W., Samaan, M. A., Ye, B. D., Yarandi, S., Germinaro, M., Shipitofsky, N., Miao, Y., Zhang, H., Dignass, A., Sands, B. E., Hisamatsu, T. & Peyrin-Biroulet, L. (2026). Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. The American journal of gastroenterology.
- Shahrokh, D. K., Vender, R. B., Lynde, C. W., Rao, J., Afif, W., Steinhart, A. H., Narula, N., Sutton, E., Thorne, C. & Bessette, L. (2026). Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). Rheumatology and therapy.
- Niyigena, E., Hoffert, Y., Afif, W., Pedicelli, A., Roblin, X., Hanžel, J., Papamichael, K., Kobayashi, T., Elens, L., Wang, Z., Ferrante, M., Verstockt, B., Vermeire, S., Vande Casteele, N., Battat, R. & Dreesen, E. (2026). Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis. Journal of Crohn's & colitis, vol. 20.
- Moura, C. S., Etingin, A., Lukusa, L., Singh, H., Narula, N., Targownik, L. E., Leung, Y., Zezos, P., Polewiczowska-Nowak, B., Afif, W. & Bernatsky, S. (2026). Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World journal of gastroenterology, vol. 32, p. 114580.
- Kritzinger, J., Candel, I., Kotrri, G., Nadeem, H., Afif, W., Bitton, A., Wild, G., Bessissow, T. & Lakatos, P. L. (2025). Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World journal of gastroenterology, vol. 31, p. 114355.
- Avinashi, V., Gupta, M., Payne, B. A., Amhaz, H., Temirova, A. T., Afif, W., Ashok, D., Barkey, J., Burnett, D., Bush, J. W., Cameron, S., Carr, S., El Demellawy, D., Erdle, S., Huynh, H. Q., Griffin, J., Grover, S. C., Grzywacz, K., Jeimy, S., Ko, H. H., Lacuesta, G., Marcon, M., Mayrand, S., Petropolis, H., Rodrigues, D., Sherlock, M., Song, C., Tardio, N., Vander Leek, T. K., Vurzinger, M., Williams, B., Xenodemetroupolous, T., Ma, C. & Chan, E. S. (2025). Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 207-227.
- Oketola, B., Bernatsky, S., Lukusa, L., Moura, C. S., Neville, A., Leung, Y., Narula, N., Afif, W., Birck, M. G., Zezos, P., Singh, H. & Canadian IBD Research Consortium (2026). Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry. Gastro hep advances, vol. 5, p. 100821.
- Pedicelli, A., Bessissow, T. & Afif, W. (2025). Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. Journal of clinical medicine, vol. 14.
- Avinashi, V., Gupta, M., Payne, B. A., Amhaz, H., Temirova, A. T., Afif, W., Ashok, D., Barkey, J., Burnett, D., Bush, J. W., Cameron, S., Carr, S., Demellawy, D. E., Erdle, S., Huynh, H. Q., Griffin, J., Grover, S. C., Grzywacz, K., Jeimy, S., Ko, H. H., Lacuesta, G., Marcon, M., Mayrand, S., Petropolis, H., Rodrigues, D., Sherlock, M., Song, C., Tardio, N., Vander Leek, T. K., Vurzinger, M., Williams, B. A., Xenodemetropoulos, T., Ma, C. & Chan, E. S. (2025). Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, vol. 21, p. 47.
- Ongay, J., Candel, I., Bitton, A., Afif, W., Bessissow, T. & Lakatos, P. L. (2025). Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare - the Double-Edged Sword. Case reports in gastroenterology, vol. 19, p. 637-643.
Voir aussi
